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Introduction: Pain remains the most important problem for people with rheumatoid arthritis (RA). Active
inflammatory disease contributes to pain, but pain due to non-inflammatory mechanisms can confound the
assessment of disease activity. We hypothesize that augmented pain processing, fibromyalgic features, poorer
mental health, and patient-reported 28-joint disease activity score (DAS28) components are associated in RA.
Methods: In total, 50 people with stable, long-standing RA recruited from a rheumatology outpatient clinic were
assessed for pain-pressure thresholds (PPTs) at three separate sites (knee, tibia, and sternum), DAS28, fibromyalgia,
and mental health status. Multivariable analysis was performed to assess the association between PPT and DAS28
components, DAS28-P (the proportion of DAS28 derived from the patient-reported components of visual analogue
score and tender joint count), or fibromyalgia status.
Results: More-sensitive PPTs at sites over or distant from joints were each associated with greater reported pain,
higher patient-reported DAS28 components, and poorer mental health. A high proportion of participants (48%)
satisfied classification criteria for fibromyalgia, and fibromyalgia classification or characteristics were each associated
with more sensitive PPTs, higher patient-reported DAS28 components, and poorer mental health.
Conclusions: Widespread sensitivity to pressure-induced pain, a high prevalence of fibromyalgic features, higher
patient-reported DAS28 components, and poorer mental health are all linked in established RA. The increased
sensitivity at nonjoint sites (sternum and anterior tibia), as well as over joints, indicates that central mechanisms
may contribute to pain sensitivity in RA. The contribution of patient-reported components to high DAS28 should
inform decisions on disease-modifying or pain-management approaches in the treatment of RA when inflammation
may be well controlled.Introduction
Rheumatoid arthritis (RA) is a common chronic systemic
inflammatory disease that causes pain and disability. Pain
in active RA may reflect synovitis, but not all people with
RA respond to antiinflammatory treatment, and other pain
mechanisms may be important. Noninflammatory pain
mechanisms in RA may include variations in central pain
processing, or coincidental pathology. Pain phenotypes in* Correspondence: David.walsh@nottingham.ac.uk
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unless otherwise stated.patients with RA that include widespread pain, mood
disturbance, and fatigue overlap with those in fibromyalgia
(FM). Fibromyalgia may represent either comorbidity or a
continuous phenotypic spectrum associated with variations
in central pain processing [1]. Noninflammatory pain
mechanisms in RA may share some common characteris-
tics with those found in other arthropathies, such as
osteoarthritis (OA), in which greater sensitivity to pain at
nonjoint sites, as well as at sites affected by arthritis, may
indicate augmented central pain processing [2]. Previous
studies have identified and partially characterized people
with RA who fulfill classification criteria for FM [3]. In
general, people with RA and FM show higher pain, higher
measures of disease activity, and poorer mental health, butntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be associated with greater pain sensitivity [6].
The 28-joint disease activity score (DAS28) is commonly
used in RA as a clinical measure of inflammatory disease
activity and to guide treatment decisions [7,8]. It appears
that higher pain levels contribute to higher DAS28 scores
[9,10]. DAS28 combines four discrete components into an
overall measure of RA inflammatory disease activity; a
28-swollen joint count (SJC), 28 tender-joint count (TJC),
acute-phase response (commonly the erythrocyte sedimen-
tation rate (ESR)), and a general health assessment using a
visual analogue score (VAS-GH). Of these components,
SJC and acute-phase response are observed by the assessor,
and VAS and TJC are reported by the patient. DAS28-P is
a derived index for the contribution of patient-reported
components to the DAS28, which, we have proposed, may
provide a quantitative assessment of noninflammatory
contributions to pain in early RA. A high DAS28-P was
associated with worse pain and disability in early RA [11],
and DAS28-P may be high in people with FM [12]. Tender-
ness may be associated with augmented pain processing
and other features of FM in RA, and DAS28 scores may
overestimate inflammatory disease activity in people with a
highTJC [12,13]. The DAS28-P index is currently a research
tool and has not been validated previously as a measure of
augmented pain in people with long-standing RA.
Quantitative sensory testing can be used to assess pain
mechanisms [14]. Pressure pain-detection thresholds
(PPTs) measure the intensity required for blunt pressure
stimuli to produce pain. Differences in PPTs between
individuals at sites distant to tissue injury may indicate
augmented central pain processing [2]. In this study, we
hypothesized that, in people with RA on stable disease-
modifying treatment, pain sensitivity, measured by lower
PPTs, is associated with a high contribution of patient-
reported factors to DAS28 and with features of FM.
Associations between higher DAS28-P indices and pain
sensitivity or FM would support interpretation of DAS28-
P as a measure of augmented pain processing. We also
aimed to explore, within a single patient group, associa-
tions between pain sensitivity, FM classification, mental
health, and their effects on disease-activity assessment.
Methods
A consecutive sample of 50 participants with RA of >2-
year duration, who reported current pain and displayed
DAS28 > 3.1 [11], were recruited to participate in a study
of pain in RA from a rheumatology outpatients clinic
at Sherwood Forest Hospitals NHS Foundation Trust
during a 3-week period in 2013. Written, informed
consent was obtained as per the Declaration of Helsinki.
Ethical approval for this project was obtained from the
East Midlands NREC–Nottingham 2 (13/EM/0047). The
American College of Rheumatology/European LeagueAgainst Rheumatism criteria 2010 [15] were used to
determine RA classification.
Clinical assessment
Demographic data, age, gender, ethnicity, smoking status,
current drug regimen, and recent analgesia were collected
at examination. The DAS28-ESR was derived from clinical
assessment by a single observer (NJ) who was blinded to
questionnaire responses.
Participants completed a questionnaire set for pain
status and other patient-reported characteristics. These
questionnaires were chosen because they have been used
in previous research to measure pain experience, beliefs,
and emotional status. The set consisted of Short Form
McGill Pain Questionnaire [16]; Intermittent and Constant
Osteoarthritis Pain (ICOAP) [17]; Beck Depression Inven-
tory (BDI) [18]; State-Trait Anxiety Index short form
(STAI-SF) [19]; Fatigue Severity Scale (FSS) [20]; Wide-
spread Pain Index (WPI) [21]; Symptom Severity Scale
(SSS) [22]; and a 0 to 10 numerical rating scale (NRS) for
current knee pain. WPI and SSS questionnaires were
included to permit FM classification according to the
American College of Rheumatology criteria 2010 [22]. A
summation of the WPI and SSS questionnaire scores was
used as a measure of fibromyalgia [23].
Pressure-pain detection thresholds
Participants undertook quantitative sensory testing for
pressure-pain detection thresholds (PPT), by using an
electronic pressure algometer with a laptop recording/
display device and a patient switch (Somedic Sensebox).
It was carried out by a single, trained observer (NJ) at
the medial tibiofemoral joint line of the most painful
knee, or the right knee if no pain existed in either, and
also at sites distal to (anterior tibia) and distant from
(sternum) the index knee. Knee pain is a common
source of disability in people with RA, and PPT assess-
ment has been standardized by us and others at these
sites in people with OA [2,24], permitting comparison
between conditions.
Participants were first familiarized with the procedure
by applying the stimulus to a learning site on one hand.
PPTs were then measured sequentially at sternum, medial
knee, and anterior tibia. For each test, the pressure (kPa)
was recorded at which pain was first experienced during
application of progressively increasing pressure by using a
probe with a 1 cm2 blunt end and a constant ramp of 50
kPa per second [25]. The test stimulus was applied to each
site/3 times with 1-minute intervals between repeats and
between sites.
Statistics
The mean of the three PPT values for each site was log
transformed to ensure normality before analysis. For the
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values was used, because pilot analyses indicated that
measurement 1 was significantly lower than measure-
ments 2 and 3. Normal distributions after transformation
were confirmed by Kolmogorov-Smirnov tests. DAS28-P
was derived from the components of the DAS28 scores, as
previously reported [11], by using a rearrangement of the
DAS28-ESR formula; DAS28-P = (0.56 × √TJC + 0.014 ×
VAS-GH)/DAS28. Pearson (parametric) or Spearman
(nonparametric) correlations were used to assess the
association between continuous variables, and Student t
tests (parametric) or Mann–Whitney U tests (nonparamet-
ric) were used to determine differences between groups.
Univariate test results are presented without adjustments
for multiple comparisons. Multivariable regression models
were used to adjust for predefined confounding variables
during analyses. Multiple linear regression was used
with continuous outcome variables (for example, log-
transformed PPT) and binary logistic regression, with all
co-variables entered simultaneously, calculated adjusted
odds ratios (aOR).
For logistic regression, the continuous independent
variables were divided into tertiles. Each regression
model included age and gender to adjust for commonTable 1 Participant characteristics
N
Female
Age
Current smoker
Analgesia Any
Paracetamol
NSAID
Opiate
DMARD Methotrexate
Sulfasalazine
Other nonbiologic DMARD
Combination nonbiologic DMARD
Biologic therapy
Combination therapy
Glucocorticosteroid
Pressure pain threshold
Knee
Tibia
Sternum
Demographics of the entire study group and a comparison between participants th
DMARDs were azathioprine (n = 2), leflunomide (n = 4), gold (n = 3), hydroxychloroq
factor agents (n=4), rituximab (n=1), or abatacept (n=1). Combination DMARDs; two or
who did not satisfy criteria for fibromyalgia).confounders. The statistical software used was the
Statistical Package for Social Scientists (SPSS) v. 21, and
statistical significance was taken as P < 0.05.Results
Participant demographics, clinical measures, PPT, and
drug regimens are shown in Table 1. The majority of
participants were using analgesics, and all were using at
least one traditional or biologic DMARD and/or gluco-
corticoid. No participant had used tricyclic antidepres-
sants, gabapentin, or pregabalin within 24 hours before
assessment. Current knee pain (NRS > 0) was reported
by 40 (80%) participants. All participants had DAS28
scores >3.1, consistent with active RA [7], and eight
participants (16%) displayed high disease activity
(DAS28 > 5.1). Data from PPT, DAS28-P, DAS28, and
all questionnaires (except for knee pain) did not signifi-
cantly diverge from normal distributions. DAS28 scores
were higher in those currently using biologics (biologics
mean (SD) = 5.5 (1.0) compared with nonbiologics
(mean (SD) = 4.6 (0.9); P < 0.05), and in those using ste-
roids (steroids mean (SD) = 5.5 (0.9) compared with no
steroid mean (SD) = 4.5 (0.8), P < 0.05).Whole study group Fibromyalgia classification
Median (IQR) or % Yes No
50 24 26
76% 75% 77%
60 (54–69) 58 (54–66) 63 (54–70)
21% 26% 17%
69% 71% 65%
63% 71% 54%
16% 17% 15%
37% 38% 35%
59% 50% 65%
22% 15% 25%
36% 40% 30%
24% 29% 15%
12% 8% 16%
31% 33% 27%
20% 15% 21%
173 (119–287) 133 (58–181)** 239 (169–470)
140 (98–246) 108 (61–167)** 187 (122–337)
155 (85–211) 111 (70–175)** 179 (149–256)
at did or did not satisfy fibromyalgia-classification criteria. Other nonbiologic
uine (n = 6), and cyclosporin (n = 3). Biologic therapies were antitumor-necrosis
more biologic or nonbiologic DMARDs. **P < 0.01 (compared with participants
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PPT values are shown in Table 1. PPTs were lower (more
sensitive) at the anterior tibia and sternum than at the
medial tibiofemoral joint line (P = 0.007 and P = 0.005,
respectively), but PPT at each site was significantly cor-
related with PPT at each other site (r > 0.64, P < 0.001 for
all associations). Low PPT at each site was associated
with higher reported pain, irrespective of the site or
aspect of pain addressed by the questionnaire (Table 2).
Lower PPT (more sensitive) at each site was also asso-
ciated with higher DAS28 and DAS28-P (Table 2).
DAS28-P and DAS28 were positively correlated (r = 0.73;
P < 0.001) (Table 1), which had the potential to confound
analyses strongly. Each component of the DAS28 score
was therefore examined for association with PPTs. Asso-
ciations between PPT and DAS28 were attributable to
significant associations with the patient-reported compo-
nents of DAS28 (VAS-GH and tender-joint count),
whereas significant associations were not detected with
ESR or swollen-joint counts, both in univariate (Table 2)
and in multivariable analyses that included all four of
theDAS28 components (Table 3). Lower PPTs were also
associated with low mood or somatic symptoms, but
were not significantly associated with reported anxiety
(Table 2), gender or age, nor with analgesic (including
opioid) or combination DMARD use (data not shown).Table 2 Associations of clinical characteristics with pressure p
DAS28
TJC
VAS-GH
SJC
ESR
DAS28-P
Pain McGill Pain Questionnaire Continuous
Intermittent
Neuropathic
Affective
Total score
ICOAP Constant
Intermittent
Knee pain
Widespread Pain Index
Fatigue Fatigue Severity Scale
Mood Beck Depression Index II
State-Trait Anxiety Index
Somatic symptoms scale
Fibromyalgia
Negative values indicate that higher levels of trait are associated with lower PPTs (m
shown. Fibromyalgia is calculated from Widespread Pain Index + Somatic SymptomFibromyalgia classification and fibromyalgia
Twenty-four (48%) participants satisfied FM classification
criteria based on responses to WPI and SSS question-
naires. Participants displayed similar demographic charac-
teristics and drug use whether or not they satisfied FM
classification criteria (Table 1). Participants who satisfied
FM classification criteria displayed lower PPT at each site
(Table 1). Associations between PPT and FM classification
were confirmed in logistic regression analyses (aOR (95%
CI) for tertiles of either the anterior tibia PPT, 0.4 (0.2 to
0.9), P = 0.035; the medial knee joint line 0.2 (0.1 to 0.5),
P = 0.001; or the sternum 0.3 (0.1 to 0.7), P = 0.007).
Participants who satisfied FM classification criteria also
displayed higher DAS28 or DAS28-P (Table 4). Associa-
tions were attributable to significant univariate associations
with the patient-reported components of DAS28 (VAS-GH
and tender-joint count) but not ESR or swollen-joint
counts (Table 4). Logistic regression using all four DAS28
components confirmed that VAS-GH was significantly
associated with FM classification (aOR (95% CI) 3.7 (1.4 to
9.5), P = 0.008), whereas TJC, SJC, and ESR were not
(aOR (95% CI) 1.5 (0.6 to 4.1), P = 0.403, 1.1 (0.5 to 2.6),
P = 0.789 and 0.8 (0.4 – 1.9), P = 0.673, respectively).
The summated (WPI + SSS) measure of fibromyalgia
had a mean (SD) of 13 (6), a median (IQR) 12 (8 to 17),
and a range from 4 to 26. DAS28 and DAS28-P were eachain-detection thresholds
Medial knee Tibia Sternum
−0.62** −0.62** −0.60**
−0.53** −0.50** −0.48**
−0.52** −0.46** −0.52**
−0.04 0.03 −0.04
−0.12 −0.21 −0.14
−0.46** −0.41** −0.41**
−0.43** −0.60** −0.47**
−0.41** −0.41** −0.40**
−0.45** −0.49** −0.38**
−0.30* −0.43** −0.33*
−0.47** −0.57** −0.46**
−0.34** −0.39** −0.35*
−0.35* −0.56** −0.41**
−0.53** −0.49** −0.46**
−0.36* −0.40** −0.33*
−0.27 −0.33* −0.27
−0.40** −0.35* −0.36*
−0.24 −0.16 −0.12
−0.28* −0.30* −0.27*
−0.44** −0.41** −0.39**
ore sensitive). Unadjusted correlation coefficients for log-transformed PPT are
s Scale. **P < 0.01, *P < 0.05 for significance of association.
Table 3 Multivariable associations of pressure-pain
detection thresholds (PPTs) with DAS28 components
DAS28 component Medial knee Tibia Sternum
β P β P β P
Patient-reported TJC −0.37 0.030 −0.42 0.017 −0.29 0.092
VAS-GH −0.33 0.047 −0.22 0.195 −0.38 0.029
Observed SJC −0.08 0.539 −0.03 0.842 −0.05 0.719
ESR −0.07 0.614 −0.22 0.134 −0.10 0.950
Standardized β values and P values (not corrected for multiple comparisons)
are shown for three regression models comparing the influence of DAS28
components on PPT. Multiple linear regression models with log-transformed
PPT at each testing site as dependent variable, and TJC, VAS-GH, SJC, ESR, age,
and gender as predictor variables.
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Associations with fibromyalgia were attributable to sig-
nificant associations with questionnaire scores in each
of WPI (DAS28, r = 0.43, P = 0.002, and DAS28-P
r = 0.43, P = 0.003) and SSS (DAS28 r = 0.34, P = 0.019,
and DAS28-P r = 0.32, P = 0.028), and due to significant
associations of the patient-reported components of
DAS28 (VAS-GH and tender-joint count), but not ESR or
swollen-joint counts (Table 4). For the WPI, correlation
coefficients (P values) for TJC, VAS-GH, SJC, and ESR
were 0.33 (P = 0.02); 0.55 (P < 0.001); 0.01 (P = 0.94) andTable 4 Associations of clinical characteristics with fibromyalg
Fib
Ye
DAS28 4.8
TJC 11
VAS-GH 70
SJC 1 (
ESR 19
DAS28-P 0.5
Pain McGill Pain Questionnaire Continuous 5.3
Intermittent 4.0
Neuropathic 3.2
Affective 4.0
Total score 3.8
ICOAP Constant 42
Intermittent 42
Knee pain 7 (
Widespread Pain Index 10
Fatigue Fatigue Severity Scale 52
Mood Beck Depression Index II 16
State-Trait Anxiety Index 0 (
Somatic symptoms scale 9 (
Differences between DAS28, DAS28-P, individual score components, and mental health
criteria, plus correlations of these variables with fibromyalgia, calculated from the sum
**P < 0.01 for differences between groups, or associations.0.00 (P = 0.99), respectively. For SSS, correlation coeffi-
cients (P values) for TJC, VAS-GH, SJC, and ESR were
0.24 (P = 0.09); 0.47 (P = 0.001); −0.04 (P = 0.81), and 0.09
(P = 0.56), respectively. Higher fibromyalgia score was as-
sociated with lower PPTs (Table 2, Figure 1B), attributable
to significant associations with the WPI (r values < −0.35
to −0.42, each P < 0.012) and SSS (r values < −0.24
to −0.32, each P < 0.089; statistically significant at two
of three test sites) questionnaire scores. Participants
who fulfilled FM criteria or had higher fibromyalgias also
scored higher for pain, anxiety, and fatigue, and reported
lower mood (Table 4).
Multiple regression analyses confirmed that DAS28-P
was associated with FM classification (aOR (95% CI) 2.8
(1.2 to 6.4), P = 0.014) and with the summated (WPI + SSS)
measure of fibromyalgia (standardized β = 0.50, P = 0.001),
after adjustment for age and gender in both models.Discussion
We provide evidence that augmented pain processing is
associated with pain and distress in people with estab-
lished RA, and confounds assessment of inflammatory
disease activity when using DAS28. We also show that
DAS28-P has potential to be used as a marker foria
romyalgia classification Fibromyalgia
s No r P
(4.4 – 5.3)** 4.4 (3.8 – 4.9) 0.46 0.001
(7 – 18)** 6 (4 – 9) 0.35 0.012
(55 – 78)** 42 (24 – 55) 0.60 <0.001
0 – 2) 1 (1 – 2) −0.03 0.816
(8 – 29) 17 (12 – 26) 0.01 0.963
8 (0.52 – 0.64)** 0.50 (0.45 – 0.57) 0.43 0.002
(3.2 – 6.7)** 2.3 (1.8 – 3.8) 0.49 <0.001
(3.0 – 5.5)** 1.7 (0.7 – 2.8) 0.61 <0.001
(2.3 – 5.7)** 1.5 (0.8 – 3.8) 0.54 <0.001
(2.5 – 6.5)** 1.8 (0.3 – 4.0) 0.53 <0.001
(3.2 – 5.8)** 2.2 (1.1 – 3.1) 0.65 <0.001
(8 – 65)** 8 (0 – 35) 0.45 0.001
(29 – 58)** 8 (0 – 32) 0.57 <0.001
5 – 8)** 3 (0 – 6) 0.50 <0.001
(7 – 13)** 4 (2 – 4) 0.86 <0.001
(38 – 61)* 39 (25 – 57) 0.46 0.001
(10 – 30)* 13 (8 – 18) 0.43 0.003
−6 – 3)** –6 (–9 – –2) 0.39 0.006
7–10)** 4 (3 – 7) 0.83 <0.001
questionnaire scores for participants who did or did not satisfy fibromyalgia
mated Widespread Pain Index and Somatic Symptoms Scale scores. *P < 0.05,
Figure 1 Scatter plots of (A) DAS28-P indices and (B) anterior
tibial PPT measurements versus fibromyalianess score (WPI + SSS).
Best-fitted linear regression lines for each plot are shown. Other PPT
measurements and the patient-reported components of DAS28 all
showed similar plots.
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during stable treatment with disease-modifying agents.
Low PPTs (more sensitive) were associated with greater
reported pain in patients with established RA. Low PPTs
have been associated with higher reported pain in other
chronically painful musculoskeletal conditions, including
osteoarthritis [14] and FM [26]. Low PPTs are also associ-
ated with neuropathic pain characteristics, as determined
by questionnaires [27,28], and we confirmed this associ-
ation in people with RA by using the neuropathic scale
of the McGill Pain Questionnaire. However, similar
associations were found with other pain characteristics,
suggesting that low PPTs may be a feature of chronic
musculoskeletal pain in general, rather than indicating
specifically neuropathology.
We found that PPTs over joints were correlated with
PPTs at sites distant to joints, and associations between
PPTs and reported pain, mental health, and fatigue wereequally strong at both articular and nonarticular sites.
These findings suggest that PPTs reflect general
patient-level characteristics, rather than only peripheral
sensitization in inflamed joints. Similarly, widespread
reductions in PPTs in people with OA [14] or FM [26]
have been taken to indicate augmented central pain
processing, and sensitivity to pressure has been associated
with increased activity in several brain regions during
functional MRI studies [29,30]. PPTs are lower in people
with RA than in controls [31] and generalized hyperalgesia
and allodynia occur in RA [32]. These and our data indi-
cate that low PPTs may provide evidence of augmented
central pain processing in people with RA.
We found that a high proportion (48%) of patients
attending secondary care follow-up with established RA
satisfied FM-classification criteria. Others have also
found a higher prevalence of FM in people with RA than
would be expected in the normal population [33]. In one
large U.S. longitudinal cohort study, approximately 10% of
participants with RA satisfied FM criteria at one time
point, and close to 20% satisfied FM criteria at some point
during follow-up [3]. Our participants were selected on
the basis of DAS28 > 3.1 and current pain, despite receiv-
ing stable treatment with traditional or biologic DMARDs,
and were largely attending secondary care appointments
for DMARD monitoring or annual review. People with
worse pain may be more likely to volunteer for studies of
pain. The prevalence of FM in our study may well reflect
its specific recruitment context. Overlap between features
of FM (fatigue and somatic symptoms) and RA may lead
to overclassification of FM in people with RA, although
these overlapping features may also reflect common
underlying mechanisms, or a subgroup of people with
established RA that is prone to augmented pain.
FM is itself a condition with augmented pain processing,
identified by quantitative sensory testing and functional
MRI [34]. Consistent with this, we found that participants
with RA who satisfied FM criteria also exhibited lower
PPTs than did those who did not. Associations were found
between low PPTs and worse scores on questionnaires
addressing a range of FM characteristics, including wide-
spread pain, somatic symptoms, fatigue, and low mood.
Each of these questionnaires produced data that did not
significantly diverge from normal distributions, and the
WPI and SSS, plus their summated total, were each asso-
ciated with PPTs and other fibromyalgic features. These
data are consistent with the proposal that fibromyalgia
represents a continuous trait rather than a dichotomous
comorbidity in people with RA, and that low PPT is a
component of fibromyalgia in RA.
One sixth of our participants displayed DAS28 > 5.1,
suggesting high disease activity, and the remainder satis-
fied DAS28 criteria for active RA. High DAS28 scores in
this patient group were largely determined by high VAS-
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of inflammatory disease activity in RA [10]. Lower PPTs
were associated with high VAS-GH and TJC, but not
with ESR or SJC, indicating that augmented pain process-
ing may be associated with inflated DAS28 in people with
well-controlled inflammatory disease. This confounding of
DAS28 scores was closely associated with other features
of FM.
We have previously shown that DAS28-P, the proportion
of DAS28 attributable to the patient-reported components
VAS-GH and TJC, is associated with current pain, and
predicts poor pain prognosis in people with early RA [11].
The current study further indicates associations between
DAS28-P and pain in RA of more than 2 years’ duration,
and supports our hypothesis that DAS28-P may reflect aug-
mented central pain processing in people with RA.
Participants in this study were attending for annual
review or DMARD monitoring, and the low observed
prevalence of swollen joints and elevated ESR was
consistent with well-controlled inflammation. Where
swollen joint counts and ESR contribute little to DAS28,
variations in tender-joint counts and VAS-GH may have
similar effects on both DAS28 and DAS28-P. In early
RA, where inflammation was often incompletely con-
trolled, we demonstrated only weak associations between
DAS28-P and DAS28 [11], whereas in the current study,
DAS28-P was strongly associated with DAS28 (r = 0.73).
Analysis of DAS28 components confirmed that associa-
tions of DAS28 with low PPTs and fibromyalgia were
attributable to the patient-reported DAS28 components.
Our data indicate that, for people with RA in whom
inflammatory disease is well controlled, DAS28 itself
may predominantly reflect augmented pain processing,
and should be used with great caution as a measure of
inflammatory disease activity.
Joint inflammation may itself drive augmented central
pain processing [35], and RA therefore may contribute
to the development of FM [3]. However, associations of
FM with poorer mental health and with fatigue, in both
RA and non-RA populations, indicate that factors in
addition to synovitis may be associated with the develop-
ment of augmented pain processing and fibromyalgia in
RA. Our data indicate that changes in pain processing
may persist after synovitis has settled, but further re-
search is required to determine possible contributions
of central processing to pain in people with active syno-
vitis. The lack of significant associations between SJC
or ESR and PPT suggests that ongoing inflammation
was not the predominant drive for pain sensitivity in
these patients, but interventional studies would be
required to determine whether more intensive suppres-
sion of inflammation in early arthritis could reduce the
contribution of augmented processing to pain even after
inflammation is controlled.Our research has several limitations, being a cross-
sectional study of an RA population on stable treatment
within a secondary-care context. Fibromyalgia can affect
many aspects of life quality on which data were not col-
lected in the current study, including sleep disturbance
and loss of concentration/memory. Additional factors
not anticipated in our study may have confounded some
of our findings.
The use of 28 swollen-joint counts and ESR to measure
inflammation in RA also has limitations. ESR might be
within the normal range in people with active RA [36],
and DAS28 does not address feet, which might be a site
of synovitis. Future studies could use ultrasound or mag-
netic resonance imaging to determine whether subclinical
inflammation might contribute to pain or reduced pain-
detection thresholds in people with RA, and whether
more-intensive immunosuppression might further improve
pain outcomes. Participants were using a range of analgesic
medications, which may have affected pain reporting and
PPTs, although post hoc analyses did not reveal any associ-
ation between analgesic use and PPTs in our study group.
Our findings may be limited to the specific PPT protocol
used, including sequence of test sites, and further research
would be required to determine whether conclusions can
be generalized to other quantitative sensory testing modal-
ities, such as thermal pain thresholds.
It is unclear from our cross-sectional study whether
augmented pain processing exacerbates pain in RA,
whether chronic pain, as experienced in RA, leads to
changes in pain processing, or whether confounding
factors contribute to the observed associations. It is likely
that altered pain processing may both contribute to and
be a consequence of joint pathology. Associations of pain
and PPT with FM measurement, both in the current
and in previous [10,13] studies, additionally support the
concept that comorbidity may contribute to both pain
severity and reduced pain thresholds in RA. Further
prospective research is merited to explore whether and
which PPT methodologies could be used to identify a
subgroup of people with RA who may benefit from
treatments that target pain processing. Aspects of
procedure, equipment, and cut-off PPT values may each
affect the validity of PPT in defining patient subgroups.
Pain remains a major problem for people with RA, and
we have shown that pain remains problematic despite in-
flammatory disease control with traditional and biologic
DMARDs [11]. Our study confirms interrelations that
have been inferred from previous studies between aug-
mented pain, mental health, fibromyalgic features, and
measures of RA disease activity [4,5,13,37]. Augmented
pain processing may be associated with poor pain progno-
sis in people treated with traditional antiinflammatory
strategies, especially in people with high DAS28-P [11].
Further escalation of traditional or biologic DMARD is
Joharatnam et al. Arthritis Research & Therapy  (2015) 17:11 Page 8 of 9unlikely to control the pain and distress associated with
augmented central pain processing, but may result in
important adverse events. Other pharmacologic, psy-
chological, and physiotherapeutic approaches may be
helpful for people with augmented pain processing
associated with other forms of chronic musculoskeletal
pain, such as FM or low back pain [38-40], and should
continue to be investigated in people with RA [41].
There is potential for DAS28-P, individual DAS28 com-
ponents, or PPTs to offer stratification tools for selecting
patients for specific treatments, but their potential should
first be examined in larger, generalizable populations and
validated in prospective studies. At present, clinicians
should consider both inflammatory disease activity and
augmented central pain processing as potential mediators
of pain, and plan treatment based on holistic assessment
in partnership with patients with RA.
Conclusions
 People with established RA commonly satisfy
fibromyalgia classification criteria, and these people
report poorer mental health and display increased
pain sensitivity to pressure at nonarticular sites.
 Fibromyalgic symptoms, sensitivity to pain, and
poorer mental health are all associated with
increased DAS28 scores
 High disease-activity scores in some people with RA
may reflect augmented pain processing rather than
active inflammatory disease.
 Pain in RA should be managed alongside
inflammatory disease activity, as noninflammatory
pain mechanisms are prevalent, and suppression of
inflammation may not eliminate pain.
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